Clinical Data in Patients with Neuroendocrine Tumors
February 12th, 2018
Based on SEER database, gastroenteropancreatic neuroendocrine tumor (GEPNET) incidence has increased 6-fold from 1 in 100,000 cases to about 6 in 100,000 cases over past 3 decades. North American Neuroendocrine Tumor Society estimates that over 100,000 GEPNET patients (pts) are currently living in the United States. A common quality of life limiting symptom for GEPNET pts is diarrhea. Excessive serotonin production, short gut syndrome, steatorrhea, bile acid colitis or intestinal bacterial overgrowth are possible causes of diarrhea in these pts. A novel amino acid based oral rehydration solution (enterade) is currently being evaluated in a Phase II clinical trial for antidiarrheal effects in post bone marrow transplant patients (NCT02919670). We conducted a pilot study of enterade in neuroendocrine tumor pts with quality of life limiting diarrhea to evaluate its antidiarrheal efficacy.
Medical records of all GEPNET pts treated with enterade for symptomatic diarrhea were evaluated. Pts were treated at the Markey Cancer Center from May 2017 to January 2018.